Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 15/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8257921 | 0.90 | ADORA2A (0.48) | ADORA2AHDAC3HDAC2SIGMAR1GRM2 | |
| SCHEMBL8256580 | 0.87 | ADORA2A (0.44) | ADORA2AHDAC3HDAC2GRM2DRD3 | |
| SCHEMBL8436488 | 0.87 | ADORA2A (0.51) | ADORA2AHDAC3HDAC2SIGMAR1GRM2 | |
| SCHEMBL14922353 | 0.85 | ADORA2A (0.49) | ADORA2ASIGMAR1GRM2HTR2CDRD3 | |
| SCHEMBL14922351 | 0.82 | ADORA2A (0.48) | ADORA2AHDAC3HDAC2SIGMAR1DRD3 | |
| SCHEMBL14922349 | 0.81 | ADORA2A (0.48) | ADORA2ASIGMAR1GRM2 | |
| SCHEMBL8226041 | 0.81 | ADORA2A (0.57) | ADORA2ASIGMAR1HTR2C | |
| SCHEMBL14922350 | 0.78 | ADORA2A (0.59) | ADORA2ASIGMAR1 | |
| SCHEMBL8256412 | 0.74 | ADORA2A (0.54) | ADORA2A | |
| SCHEMBL2847129 | 0.71 | ADORA2A (0.41) | ADORA2AHDAC3HDAC2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7368449-B2 | 2-alkynyl- and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION (US) | 2008-05-06 | — | — | US | disclosed |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885HDAC3 882/4885HDAC2 1793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.